Sanofi's Praluent And Amgen's Repatha Now Set For Battle In Europe, US
This article was originally published in The Pink Sheet Daily
Executive Summary
Praluent and Repatha are ready for a transatlantic showdown after regulatory approvals in Europe and US, but the jury remains out on which PCSK9 inhibitor will gain the upper hand.
You may also be interested in...
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.
Praluent Launch Brings Clinical Practice Challenges
Despite enthusiasm about PCSK9 class, the prescribing community will have to wrestle with patient-selection criteria, uncertainty about very low LDL levels and a lack of outcomes data for Sanofi and Regeneron’s alirocumab.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.